Previous 10 | Next 10 |
2023-12-19 14:22:11 ET As an aggressive subset of equities, penny stocks offer patient investors occasional lottery ticket-like returns. However, the market gyrations around news and events also invite risk. This guide explores the fundamentals of penny stocks , how announcement...
NRx Pharmaceuticals Announces Signing of a Data and Technical Information Agreement with Columbia University Accessing Key Data Demonstrating Efficacy and Safety of Intravenous Ketamine for the Treatment of Suicidal Depression PR Newswire Ketamine, an NMDA blocker, was highl...
NRx Pharmaceuticals Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections PR Newswire "Study May Proceed" letter received from FDA Potential to initiate registrational study...
NRx Pharmaceuticals Provides Notice of Annual Meeting of Shareholders PR Newswire RADNOR, Pa. , Dec. 13, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, announced th...
NRx Pharmaceuticals to Participate in LifeSci Corporate Access Event PR Newswire RADNOR, Pa. , Dec. 11, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announc...
--News Direct-- NRx Pharmaceuticals founder and chief scientist Dr Jonathan Javitt joined Steve Darling from Proactive to discuss groundbreaking developments in treating suicidal ideation and depression. NRx focuses on targeting the NMDA (N-methyl-D-aspartate) receptor in the brain, i...
2023-11-14 19:35:31 ET NRX Pharmaceuticals, Inc. (NRXP) Q3 2023 Earnings Conference Call November 14, 2023 04:30 PM ET Company Participants Matthew Duffy - Chief Business Officer Stephen Willard - Chief Executive Officer Jonathan Javitt - Founder & Chief Scie...
NRX Pharmaceuticals Inc. (NRXP) is expected to report $-0.11 for Q3 2023
2023-11-14 03:10:14 ET More on NRx Pharmaceuticals Seeking Alpha’s Quant Rating on NRx Pharmaceuticals Historical earnings data for NRx Pharmaceuticals Financial information for NRx Pharmaceuticals For further details see: NRx Pharmaceuticals GAAP ...
NRx Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update PR Newswire Four near-term milestones, including initiation of potential spinout initiatives expected in 2023/early 2024 Completing enrollment of the originally-targeted...
News, Short Squeeze, Breakout and More Instantly...
NRX Pharmaceuticals Inc. Company Name:
NRXP Stock Symbol:
NASDAQ Market:
NRX Pharmaceuticals Inc. Website:
NRx Pharmaceuticals (NASDAQ:NRXP) to Proceed with Two New Drug Applications in 2024; NRX-101 has Been Returned to the Company for Filing PR Newswire New Drug Application (NDA) for Accelerated Approval planned for NRX-101 in people with bipolar depression and akathisia in 202...
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024 PR Newswire RADNOR, Pa. , June 20, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"...
NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Neuroscience, Information Technology and Medical Technology Veteran to its Board of Directors PR Newswire Dr. Dennis McBride brings extensive experience in Neuroscience and its interface with Information and Medical Technology ...